{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:50:29Z","timestamp":1791186629662,"version":"4.1.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2009,8,11]],"date-time":"2009-08-11T00:00:00Z","timestamp":1249948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s12031-009-9269-5","type":"journal-article","created":{"date-parts":[[2009,8,10]],"date-time":"2009-08-10T06:29:42Z","timestamp":1249885782000},"page":"135-137","source":"Crossref","is-referenced-by-count":66,"title":["Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy"],"prefix":"10.1007","volume":"40","author":[{"given":"Alfred","family":"Maelicke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Hoeffle-Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arno","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Samochocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Jordis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K. E.","family":"Koepke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,11]]},"reference":[{"key":"9269_CR1","unstructured":"Birks, J., Harvey, R., Olin, J., Schneider, L., et al. (2003\u20132007). ADAS-cog changes after 6\u00a0months of treatment, reviews of available clinical studies on FDA-approved acetylcholinesterase inhibitors. Cochrane Lib."},{"key":"9269_CR2","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/sj.npp.1300150","volume":"28","author":"B Bontempi","year":"2003","unstructured":"Bontempi, B., Whelan, K. T., Risbrough, V. B., Lloyd, G. K., & Menzaghi, F. (2003). Cognitive enhancing properties and tolerability of cholinergic agents in mice: A comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand of nicotinic acetylcholine receptors. Neuropsychopharmacology, 28, 1235\u20131246.","journal-title":"Neuropsychopharmacology"},{"key":"9269_CR3","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1124\/jpet.102.045773","volume":"305","author":"M Samochocki","year":"2003","unstructured":"Samochocki, M., H\u00f6ffle, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., et al. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. Journal of Pharmacology and Experimental Therapeutics, 305, 1024\u20131036.","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"9269_CR4","first-page":"37","volume":"151","author":"L Spowart-Manning","year":"2004","unstructured":"Spowart-Manning, L., & van der Staay, F. J. (2004). The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behavioral and Brain Sciences, 151, 37\u201346.","journal-title":"Behavioral and Brain Sciences"},{"key":"9269_CR5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/00002512-200320100-00006","volume":"20","author":"G Wilcock","year":"2003","unstructured":"Wilcock, G., et al. (2003). A long-term comparison of galantamine and donepezil in the treatment of Alzheimer\u2019s disease. Drugs Aging, 20, 777\u2013789.","journal-title":"Drugs Aging"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-009-9269-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12031-009-9269-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-009-9269-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T22:19:22Z","timestamp":1559427562000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12031-009-9269-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,11]]},"references-count":5,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["9269"],"URL":"https:\/\/doi.org\/10.1007\/s12031-009-9269-5","relation":{},"ISSN":["0895-8696","1559-1166"],"issn-type":[{"value":"0895-8696","type":"print"},{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,11]]}}}